Literature DB >> 28463521

Metabolic PET Imaging in Oncology.

Kiran Kumar Solingapuram Sai1, Zuzana Zachar2, Paul M Bingham2, Akiva Mintz1.   

Abstract

OBJECTIVE: In this article, we provide a general overview of how cancer cells subvert critical metabolic pathways to support their growth and unchecked division. Furthermore, we outline how molecular imaging can diagnostically exploit the resulting differences between cancer and normal cells.
CONCLUSION: Molecular PET can provide valuable information about the metabolic dysregulation in cancer.

Entities:  

Keywords:  FDG; PET; glutamine; metabolism; molecular imaging

Mesh：

Substances：

Year:  2017        PMID： 28463521     DOI： 10.2214/AJR.17.18112

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  9 in total

Review 1.  Metabolic requirements of pulmonary fibrosis: role of fibroblast metabolism.

Authors:  Robert B Hamanaka; Gökhan M Mutlu
Journal:  FEBS J       Date:  2021-01-03       Impact factor: 5.542

2.  Andrographolide inhibits non-small cell lung cancer cell proliferation through the activation of the mitochondrial apoptosis pathway and by reprogramming host glucose metabolism.

Authors:  Zhao Chen; Wei-Jian Tang; Yu-Han Zhou; Zhou-Miao Chen; Kai Liu
Journal:  Ann Transl Med       Date:  2021-11

3.  First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer.

Authors:  Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

4.  Assessment of 213Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-13C]pyruvate and [18F]FDG.

Authors:  Benedikt Feuerecker; Michael Michalik; Christian Hundshammer; Markus Schwaiger; Frank Bruchertseifer; Alfred Morgenstern; Christof Seidl
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

5.  Impact of Different Metal Artifact Reduction Techniques on Attenuation Correction of Normal Organs in 18F-FDG-PET/CT.

Authors:  Janna Morawitz; Ole Martin; Johannes Boos; Lino M Sawicki; Katrin Wingendorf; Martin Sedlmair; Eduards Mamlins; Christina Antke; Gerald Antoch; Benedikt M Schaarschmidt
Journal:  Diagnostics (Basel)       Date:  2022-02-01

6.  Development of an automated production process of [64 Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications.

Authors:  Tengzhi Liu; Kathrine Røe Redalen; Morten Karlsen
Journal:  J Labelled Comp Radiopharm       Date:  2022-04-29       Impact factor: 1.949

7.  Glycolysis on F-18 FDG PET/CT Is Superior to Amino Acid Metabolism on C-11 Methionine PET/CT in Identifying Advanced Renal Cell Carcinoma at Staging.

Authors:  Suk-Hyun Lee; Jee-Soo Park; Hyunjeong Kim; Dongwoo Kim; Seung-Hwan Lee; Won-Sik Ham; Woong-Kyu Han; Young-Deuk Choi; Mijin Yun
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

8.  Automated synthesis of [11C]L-glutamine on Synthra HCN plus synthesis module.

Authors:  Prashanth K Padakanti; Shihong Li; Alexander Schmitz; David Mankoff; Robert H Mach; Hsiaoju S Lee
Journal:  EJNMMI Radiopharm Chem       Date:  2019-03-20

9.  CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer.

Authors:  Sarah Erdmann; Lars Niederstadt; Eva Jolanthe Koziolek; Juan Daniel Castillo Gómez; Sonal Prasad; Asja Wagener; Jan Lennart von Hacht; Sandy Reinicke; Samantha Exner; Sebastian Bandholtz; Nicola Beindorff; Winfried Brenner; Carsten Grötzinger
Journal:  Theranostics       Date:  2019-09-19       Impact factor: 11.556
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.